The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 URO-901-3005 trial.
The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback